Alzheon may offer Bellus Shareholder upside on Alzheimer's https://www.bizjournals.com/boston/blog/bioflash/2015/04/alzheons-ceo-says-he-can-beat-biogen-with-the.html?ana=yahoo
Biogen market cap jumps $10B on news of its trial data reducing levels of protein amyloid level build up in the brain...Bellus Health, which would recieve future royalty payments on Alzheon's ALZ-801 drug, barely trades...talk about a complete disconnect between the current market value of Bellus vs. comparable companies with Ph II and Ph III Orphan/Alzheimer's drug candidates! Makes no sense.
Alzheon, Inc. ("Alzheon") of Lexington, Massachusetts, USA, has entered into a worldwide license agreement for BLU8499 and a family of analogs, along with an associated platform of chemotypes and clinical datasets. BELLUS Health will receive a portion of all future payments received by Alzheon related to BLU8499 and royalties on net sales of BLU8499. Further terms of the license agreement are not disclosed. "We believe that placing BLU8499 and the tramiprosate analog platform in the hands of a proven and experienced Alzheimer's drug development team at Alzheon will enable BELLUS Health to realize the full potential of this therapeutic asset and give us the option to derive significant future value," continued Roberto Bellini, Chief Executive Officer of BELLUS Health.
Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing the next generation of medicines for Alzheimer's and other neurodegenerative diseases. Alzheon was founded in 2013 by Martin Tolar, MD, PhD. Previously, Dr. Tolar has held a number of executive positions in life sciences companies, where he has established and grown new companies, business areas and product opportunities. Most recently he served as President and CEO of Knome, Inc., President and CEO of NormOxys, Inc. and Chief Business Officer of CoMentis, Inc.
"We believe that BLU8499 is a very promising drug candidate for the treatment of Alzheimer's disease," said Dr. Martin Tolar, Chief Executive Officer of Alzheon. "Having completed a Phase 1 clinical study, we are excited to pursue the development of BLU8499, to be named ALZ-801, into a Phase 2 proof-of-concept study in patients with Alzheimer's disease, guided by the existing clinical data and subpopulation analyses in more than 2,000 Alzheimer's patients from Phase 3 studies conducted by BELLUS Health and its predecessor Neurochem, Inc."
Read more at https://www.stockhouse.com/news/press-releases/2013/10/23/bellus-health-out-licenses-vivimind-blu8499-and-its-analogs#ZFmRRFjAHWFUijbH.99